Year: 2024 Title: REDUCE-AMI Subtitle: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction Type of Trial: A randomized, parallel-group, open-label trial Objective: To determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic … Read More
Cardiovascular Disease
EMPACT-MI: Empagliflozin after MI
Year: 2024 Title: EMPACT-MI Subtitle: Empagliflozin after Acute Myocardial Infarction Type of Trial: A double-blind, randomized, placebo-controlled trial Objective: To assess if the use of empagliflozin in the treatment of acute myocardial infarction (AMI) affects future mortality or heart failure … Read More
STEP-HFpEF DM: Semaglutide in HFpEF and DM
The study suggests that Semaglutide is effective in reducing symptoms and weight in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes when compared to a placebo
PACER Trial: Platelet Transfusion before CVC Placement
The PACER Trial: Revisiting Platelet Transfusions for CVC Placement The 2023 PACER Trial investigated a critical aspect of clinical care involving patients with thrombocytopenia undergoing central venous catheter (CVC) placement. This parallel, single-blinded, randomized controlled trial aimed to establish whether … Read More
AGENT IDE: Paclitaxel-Coated Balloon for ISR
The AGENT IDE Trial: Revolutionizing the Treatment of In-Stent Restenosis The AGENT IDE Trial, a prominent study published in 2024, has shed light on a pivotal question in cardiology: Is a paclitaxel-coated balloon more effective than an uncoated balloon for … Read More
REDUCE LAP-HF II: Atrial Shunt Device in HFpEF and HFmEF
Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More
ILUMIEN IV: OCT-Guided vs. Angio-Guided PCI
Unveiling the ILUMIEN IV Trial: A New Era of Percutaneous Coronary Intervention The ILUMIEN IV: OPTIMAL PC Trial, conducted in 2023, is a landmark study that compares the efficacy of Optical Coherence Tomography (OCT)-guided coronary stent implantation to the traditional … Read More
BYPASS-CTCA: CT Angio before Cath in Patients with CABG
The BYPASS-CTCA Trial: Enhancing Cardiac Procedures with Pre-Operative CT Scans In 2023, the BYPASS-CTCA Trial set out to redefine the pre-operative protocol for patients with a history of coronary artery bypass grafting (CABG). This open-label randomized controlled trial posed a … Read More
ARTESIA Trial: Apixaban for Subclinical AFib
ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More
DAPA-MI Trial: Dapagliflozin in MI
DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More